-

Shareholder Alert: Robbins LLP Announces ProAssurance Corporation (PRA) Accused of Misleading Shareholders

SAN DIEGO & BIRMINGHAM, Ala.--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a purchaser of ProAssurance Corporation (NYSE: PRA) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between April 26, 2019 and May 7, 2020. ProAssurance is one of the largest medical insurance providers in the U.S.

If you suffered a loss as a result of ProAssurance's misconduct, click here.

ProAssurance Corporation (PRA) Accused of Misleading Shareholders

According to the complaint, ProAssurance’s most important division is its Specialty Property and Casualty segment (“Specialty P&C”), which has accounted for at least 60% of its gross premiums written since 2015. In 2016, ProAssurance underwrote a very large specialty policy for one large healthcare provider customer, assuring investors that its reserves were "adequate" and "appropriate," and reflecting a "conservative view" when established. Despite assurances, on January 22, 2020, ProAssurance revealed that it was estimating a $37 million adverse development in its Specialty P&C loss reserves for fourth quarter 2019 due to a deteriorating loss experience related to the large account underwritten in 2016. Then one month later, ProAssurance revealed that the adverse development from the 2016 underwritten account was actually $51.5 million rather than the initial estimate of $37 million. Finally, on May 8, 2020, ProAssurance disclosed that its large healthcare client would likely not renew its policy and instead would exercise an option for tail coverage that would result in an additional $50 million in losses, for an aggregate of over $100 million in losses on a single account. Following all of these disclosures, ProAssuranc's stock fell nearly 57% from a closing price of $37 per share on January 22, 2020, to close at $15.95 per share on May 8, 2020.

ProAssurance Corporation (PRA) Shareholders Have Options

Contact us to learn more:
Leo Kandinov
(800) 350-6003
lkandinov@robbinsllp.com
Shareholder Information Form

Want to be notified if a class action on behalf of ProAssurance settles? Want to receive free alerts about companies engaged in wrongdoing? Sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

Robbins LLP

NYSE:PRA

Release Versions
$Cashtags

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Robbins LLP Informs Investors of the FS KKR Capital Corp. Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired FS KKR Capital (NYSE: FSK) securities between May 8, 2024 and February 25, 2026. FS KKR Capital is a private credit firm, also known as Business Development Company, which specializes in making private loans to companies.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: Ro...

Robbins LLP Urges GOSS Stockholders to Contact the Firm for Information About the Class Action Against Gossamer Bio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Gossamer Bio, Inc. (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026. Gossamer is a clinical stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension (PH) associated with interstitial lung disease.For more information, submit a form, email att...

Robbins LLP Urges IBRX Stockholders to Contact the Firm for Information About the Class Action Against ImmunityBio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ImmunityBio, Inc. (NASDAQ: IBRX) securities between January 19, 2026 and March 25, 2026. ImmunityBio is a biotechnology company and ANKTIVA is the Company's lead biologic product. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What is the class period? January 19, 2026 – March 25, 202...
Back to Newsroom